Clinical Trial Update: Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing SKF101804 Cefixime 200 mg/5 mL suspension to the reference cefixime 200 mg/5 mL suspension in healthy adults under fast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Bacterial

Drugs mentioned

• Cefixime 200 mg/5 mL suspension (reference product) (cefixime)
• SKF101804 Cefixime 200 mg/5 mL suspension (cefixime)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Bacterial | Phase 1 | Status: COMPLETED | Results posted: 2019-03-22